Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.

You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-Bcr-Abl-Flumbatinib
Flumbatinib

Chemical Structure : Flumbatinib

CAS No.: 895519-90-1

Flumbatinib (HH-GV678, HH-GV-678)

Catalog No.: PC-38393Not For Human Use, Lab Use Only.

Flumatinib (HH-GV678) is a potent BCR-ABL/PDGFR/KIT inhibitor, potently inhibits ABL, PDGFR-β and KIT kinase with IC50 of 1.2, 307.6 and 665.5 nM, respectively.

Packing Price Stock Quantity
10 mg $88 In stock
25 mg $148 In stock
50 mg $248 In stock
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Flumatinib (HH-GV678) is a potent BCR-ABL/PDGFR/KIT inhibitor, potently inhibits ABL, PDGFR-β and KIT kinase with IC50 of 1.2, 307.6 and 665.5 nM, respectively.
Flumatinib (HH-GV678) displays only weak inhibition of VEGFR2/3, SRC, FLT3, RET, EGFR, and HER2.
Flumatinib (HH-GV678) is a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib (IC50=100.9 nM).
Flumatinib (HH-GV678) exhibited a selective inhibition pattern toward imatinib-resistant KIT mutants associated with GISTs, effectively overcame the drug resistance of certain KIT mutants with activation loop mutations (i.e., D820G, N822K, Y823D, and A829P).
Flumatinib (HH-GV678) had superior efficacy compared with imatinib or sunitinib against 32D cells with the secondary mutation Y823D.

Physicochemical Properties

M.Wt 562.601
Formula C29H29F3N8O
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide

References

1. Luo H, et al. Leukemia. 2010 Oct;24(10):1807-9.

2. Kuang Y, et al. Cancer Chemother Pharmacol. 2020 Sep;86(3):339-346.

3. Zhang L, et al. Clin Cancer Res. 2021 Jan 1;27(1):70-77.

4. Zhao J, et al. Cancer Sci. 2014 Jan;105(1):117-25.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: